William Wesemann
William Wesemann's purchase track record
How the stock did after each of William Wesemann's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/6/2026 | ACON | $5K | -28.1% | pending | — |
| 3/12/2024 | LPSN | $100K | -37.6% | +4.0% | +6.2% |
| 3/23/2023 | LPSN | $78K | +15.4% | +15.6% | +9.7% |
| 4/21/2022 | ACON | $48K | -69.1% | -70.0% | -16.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
ACON Adds NYU Langone Health to CLARITY Trial Network. Aclarion Inc. announced that NYU Langone Health has joined its CLARITY Trial Network. The partnership brings the health system into 11 enrolling sites, expanding the company’s clinical trial footprint. This move could increase the pace of data collection for Aclarion’s pipeline. The announcement comes as the stock trades near its 14‑day support level.
Transaction History
| LPSN | ▼ Sell | Other | 43,655 | — | 9/4/2026 | View on chart |
| ACON | ▲ Buy | Grant | 20,000 | $0 | 6/11/2026 | View on chart |
| ACON | ▲ Buy | Open Market | 1,562 | $5K | 5/6/2026 | View on chart |
| LPSN | ▲ Buy | Grant | 200,000 | $0 | 8/25/2025 | View on chart |
| LPSN | ▲ Buy | Grant | 80,000 | $0 | 12/16/2024 | View on chart |
| LPSN | ▲ Buy | Open Market | 100,000 | $100K | 3/12/2024 | View on chart |
| LPSN | ▲ Buy | Grant | 59,881 | $0 | 10/5/2023 | View on chart |
| LPSN | ▲ Buy | Open Market | 20,000 | $78K | 3/23/2023 | View on chart |
| LPSN | ▲ Buy | Grant | 13,124 | $0 | 8/4/2022 | View on chart |
| LPSN | ▲ Buy | Option Exercise | 15,000 | $268K | 5/2/2022 | View on chart |
| ACON | ▲ Buy | Open Market | 11,000 | $48K | 4/21/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Senators push for AI disclosure rules affecting LPSN
US senators are moving to force AI companies to disclose more information, a development that could impact LivePerson's regulatory environment. As an AI-focused company, LPSN may face new compliance requirements under such legislation. The stock is currently trading well below its 52-week high, with analysts setting a moderate price target.
Senators push for AI disclosure rules affecting LPSN. US senators are moving to force AI companies to disclose more information, a development that could impact LivePerson's regulatory environment. As an AI-focused company, LPSN may face new compliance requirements under such legislation. The stock is currently trading well below its 52-week high, with analysts setting a moderate price target.